CAPTOR THERAPEUTICS
Captor Therapeutics is a bio-pharmaceutical firm focused on development of protein degradation drugs for cancer and autoimmune diseases. Targeted Protein Degradation (TPD) combats the therapeutic limits of small molecules with overcoming drug resistance and uncoupling their pharmacokinetics from pharmacodynamics. Breakthrough TPD technology allows degradation of virtually any intracellular protein including the so-called "undruggable proteome".
CAPTOR THERAPEUTICS
Industry:
Biopharma Biotechnology Medical
Founded:
2017-01-01
Address:
Wroclaw, Dolnoslaskie, Poland
Country:
Poland
Website Url:
http://www.captortherapeutics.com
Total Employee:
51+
Status:
Active
Contact:
+48 537 869 089
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Nginx Microsoft Exchange Online Office 365 Mail Google Apps For Business
Similar Organizations
Enzyvant Sciences
Enzyvant Sciences is a biotechnology company which focuses on developing treatments for rare diseases.
Lipofabrik
Lipofabrik produces and markets biological and biodegradable molecules produced through bioprocesses based on renewable resources.
Mast Therapeutics
Mast Therapeutics is a biopharmaceutical company developing novel, clinical-stage therapies for serious or life-threatening diseases.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Current Employees Featured
Stock Details
Official Site Inspections
http://www.captortherapeutics.com Semrush global rank: 8.93 M Semrush visits lastest month: 231
- Host name: 26.ibc.pl
- IP address: 94.152.195.126
- Location: Poland
- Latitude: 52.2394
- Longitude: 21.0362
- Timezone: Europe/Warsaw
More informations about "Captor Therapeutics"
Captor Therapeutics
Co-founder and SVP Chemistry of Captor Therapeutics who builds scientific strategy and oversees chemistry efforts. Prior to Captor, served as Global Head at Center for Proteomic โฆSee details»
Captor Therapeutics
Captor Therapeutics' Optigradeโข platform is a powerful drug discovery engine. At Captor, we leverage cutting-edge technologies and multidisciplinary expertise to quickly identify and develop novel drugs that target high-value therapeutic areas.See details»
Captor Therapeutics
Captor Therapeutics is an innovative biopharmaceutical group specializing in the development of drugs based on Targeted Protein Degradation (โTPDโ) and a European leader of this rapidly โฆSee details»
Captor Therapeutics - Crunchbase Company Profile & Funding
Captor Therapeutics is a bio-pharmaceutical firm focused on development of protein degradation drugs for cancer and autoimmune diseases. Targeted Protein Degradation (TPD) combats the โฆSee details»
Captor Therapeutics SA | LinkedIn
Captor Therapeutics is a publicly-listed (WSE:CTX) innovative drug discovery and development company focused on targeting the undruggable proteome using targeted protein degradation.See details»
CaptorTherapeutics - Nature
CaptorTherapeutics Wroclaw, Poland Tel: +48 570 131 570 Email:t.shepherd@ captortherapeutics.com CONTACT Optigrade platform E2 POI E2 POI Ub MG with next โฆSee details»
CAPTOR THERAPEUTICS GmbH - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for CAPTOR THERAPEUTICS GmbH of Allschwil, BASEL-LAND. Get the latest business insights from Dun โฆSee details»
Captor Therapeutics - Overview, News & Similar companies
Mar 7, 2023 Captor Therapeutics contact info: Phone number: +48 537869089 Website: www.captortherapeutics.com What does Captor Therapeutics do? Captor Therapeutics is a โฆSee details»
Captor Therapeutics SA - Drug pipelines, Patents, Clinical trials
· captortherapeutics.com. Captor Therapeutics has signed an agreement for the implementation and funding of Stage II of the CT-01 Project. ... The statistics for drugs in the Pipeline is the โฆSee details»
Captor Therapeutics - Company Profile - Tracxn
Nov 27, 2024 Email ID: *****@captortherapeutics.com; Phone Number: +48 ***** Key Metrics. Annual Revenue. 21.5M PLN ($5.6M) as on Dec 31, 2019. Which legal entities is Captor โฆSee details»
Captor Therapeutics - VentureRadar
"Captor Therapeutics is a biopharmaceutical company focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known โฆSee details»
Captor Therapeutics - Craft
Captor Therapeutics has 5 employees across 2 locations. See insights on Captor Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more โฆSee details»
Captor Therapeutics SA (Captor Therapeutics SA) - ่ฏ็ฉ็ฎก็บฟ_ไธๅฉ_ โฆ
Captor Therapeutics has signed an agreement for the implementation and funding of the Stage II of the CT-01 Project Captor Therapeutics, a biopharmaceutical company specialized in the โฆSee details»
Captor Therapeutics
Captor Therapeutics is a high-tech pharmaceutical company focused on targeting the undruggable proteome.See details»
Captor Therapeutics - businessabc.net
Feb 25, 2025 We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.See details»
NIH-funded research team engineers new drug targeting pain โฆ
Mar 5, 2025 Study of CB1 receptor has implications for chronic pain treatment. WHAT: A research team funded by the National Institutes of Health has developed a medication that โฆSee details»
CaptorTwitter - Captor Therapeutics
Oct 15, 2021 LinkedIn: @CaptorTherapeutics. Twitter: @CaptorTherapeu1 . For further information, please contact: Polish Media and Investor relations: Point of View. Jakub โฆSee details»
Captor Therapeutics Announces Three-Year Strategic Objectives
WROCลAW, Poland, March 07, 2023 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (โCaptorโ) (WSE:CTX), a leader in the development of Targeted Protein Degradation (TPD) โฆSee details»
Ono Enters a Drug Discovery Collaboration Agreement with โฆ
Nov 14, 2022 Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; โOnoโ) today announced that it has entered a worldwide drug discovery collaboration โฆSee details»
Captor Therapeutics Nominates the Molecular Glue CPT-6281
Aug 10, 2022 Polish Media and Investor relations: Point of View Bartosz Sawulski +48 694 400 787 [email protected]: International Investor Relations: LifeSci AdvisorsSee details»